By Dr. Vimal George, MD | Reviewed by CME Travel Academy Faculty · 7 min read · Reviewed June 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2026 […]
GOLD 2026 COPD Guidelines: Key Changes for Clinicians Read More »
Master the 2022 AHA/ACC/HFSA heart failure guidelines for primary care — ARNI, beta-blocker, MRA, SGLT2i, and new HFpEF therapies including SGLT2 inhibitors and GLP-1 receptor agonists. Earn CME credits.
KDIGO 2024, the four pillars, and the FLOW & CONFIDENCE trials — what primary care needs to do differently for chronic kidney disease.
Chronic Kidney Disease in Primary Care: The Four Pillars of Kidney Protection Read More »
The 2026 ADA Standards of Care and AACE Type 2 Diabetes Algorithm: earlier CGM, comorbidity-first therapy, and weight targets every clinician should know.
Diabetes Guidelines 2026: The ADA and AACE Updates Every Clinician Needs Read More »
For the first time in eight years, the American Heart Association (AHA) and the American College of Cardiology (ACC) have released a comprehensive overhaul of their hypertension guidelines. The 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults arrives at a critical moment: hypertension remains the single most
2025 AHA/ACC Hypertension Guidelines: What Every Primary Care Clinician Must Know Read More »
The Global Initiative for Asthma (GINA) released its 2026 Strategy Report on May 5, 2026, and primary care is squarely in its crosshairs. Asthma affects roughly 25 million Americans, and the majority of routine management still happens in family medicine, internal medicine, and advanced-practice offices rather than in pulmonology subspecialty suites. The 2026 update reflects
GINA 2026: What’s New in Asthma Management for Primary Care Read More »
For years, the conversation around GLP-1 receptor agonists in type 2 diabetes centered almost entirely on glucose lowering. Then came a series of landmark cardiovascular outcomes trials — LEADER, SUSTAIN-6, PIONEER 6 — and the paradigm began to shift. But until recently, one practical barrier remained: most GLP-1 receptor agonists required subcutaneous injection, limiting uptake
Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but
